about
Complement activation capacity in plasma before and during high-dose prednisolone treatment and tapering in exacerbations of Crohn's disease and ulcerative colitis.Infliximab induces clonal expansion of γδ-T cells in Crohn's disease: a predictor of lymphoma risk?Vitamin D increases programmed death receptor-1 expression in Crohn's disease.A Proposal for a Study on Treatment Selection and Lifestyle Recommendations in Chronic Inflammatory Diseases: A Danish Multidisciplinary Collaboration on Prognostic Factors and Personalised Medicine.Gastric transit and small intestinal transit time and motility assessed by a magnet tracking system.Effects of Arabinoxylan and Resistant Starch on Intestinal Microbiota and Short-Chain Fatty Acids in Subjects with Metabolic Syndrome: A Randomised Crossover Study.Detection of Pneumocystis jirovecii in oral wash from immunosuppressed patients as a diagnostic toolDiagnosis of Helicobacter Pylori Infection is Associated with Lower Prevalence and Subsequent Incidence of Crohn's Disease.How fatigue is experienced and handled by female outpatients with inflammatory bowel diseaseHigh-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23.Diagnosis and treatment of fistulising Crohn's disease.Randomised clinical trial: oral vs. intravenous iron after upper gastrointestinal haemorrhage--a placebo-controlled study.Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. A Danish 16-year nationwide follow-up study.Faecal microbiota transplantation: establishment of a clinical application framework.Occurrence of anaemia in the first year of inflammatory bowel disease in a European population-based inception cohort - An ECCO-EpiCom study.Flow cytometry detection of vitamin D receptor changes during vitamin D treatment in Crohn's disease.Pilot study trialling a new ambulatory method for the clinical assessment of regional gastrointestinal transit using multiple electromagnetic capsules.Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions.Adherence and quality of care in IBD.Gastrointestinal and liver disease in Adult Life After Childhood Cancer in Scandinavia: A population-based cohort study.Biological therapy increases the health-related quality of life in patients with inflammatory bowel disease in a clinical setting.Regional gastrointestinal transit times in severe ulcerative colitis.Immune responses and parasitological observations induced during probiotic treatment with medicinal Trichuris suis ova in a healthy volunteer.Helicobacter pylori infection is associated with reduced prevalence of colonic diverticular disease.Mucosal and systemic immune modulation by Trichuris trichiura in a self-infected individual.Faecal microbiota transplantation for recurring Clostridium difficile infection in a patient with Crohn's disease and ileorectal anastomosis.Faecal egg counts and expulsion dynamics of the whipworm, Trichuris trichiura following self-infection.Vitamin D deficiency in cirrhosis relates to liver dysfunction rather than aetiology.The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.Vitamin D3 treatment of Crohn's disease patients increases stimulated T cell IL-6 production and proliferation.Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study.Human dendritic cell antigen presentation and chemotaxis are inhibited by intrinsic 25-hydroxy vitamin D activation.Ethylene-Diamine-Tetra-Acetate (EDTA) mimics the effect of regulatory T cells in suppression assays: a potential pitfall when using AutoMACS-separated cells.First-time urea breath tests performed at home by 36,629 patients: a study of Helicobacter pylori prevalence in primary care.Health care and patients' education in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom study.Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom Study.Increased levels of circulating Th17 cells in quiescent versus active Crohn's disease.Lack of follow-up of anaemia after discharge from an upper gastrointestinal bleeding centre.Indium-labelled human gut-derived T cells from healthy subjects with strong in vitro adhesion to MAdCAM-1 show no detectable homing to the gut in vivo.Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways.
P50
Q24816696-A1D12173-383B-4300-B708-75145A54AC4FQ28741471-3D03E629-BCCA-40B8-8DFB-508B43870FD2Q33648411-5E4A6D9F-82BD-46C8-9A15-E37BA73761C7Q33749513-BD3EE738-FF51-4220-A3FB-6752D155C7A5Q34113972-3BCCA706-05E4-43AB-A048-7C36B5A61A3CQ36081669-33538B50-D0DB-4A4A-A65D-EBD318E8F6E4Q36328442-F3DD820F-DABD-444A-AA24-BE2479C2A341Q37098437-02969D0E-2FFB-49B2-B18F-2423D713BC8BQ37173848-E7A75F96-BA80-4F0C-B445-731B484D72BEQ37494947-D97C9CF5-C042-4B24-85D7-70D33348682BQ37942724-0F5C0C3D-7041-4E5C-BED6-1BCA958C39EEQ38440965-942D0802-1E4A-41F6-A77F-164D46020D32Q38500538-467E8460-9F31-459E-A5CD-26852AFF09ECQ38597887-230DC638-FBFA-4324-8E52-28BD6BF7B126Q38748245-6F9B8774-F8F2-435C-B20D-78AE82D68032Q38906846-93C09D11-EEE5-4A4E-8EDF-6FB21D770253Q39107442-CB6B6074-CB6B-4C37-8924-A5DB5C47E23DQ39177422-121A9D5C-2611-4121-8A81-68C3191DB58CQ39678169-B0439DC7-9A91-498B-88F8-2220223FCBA6Q39754759-DF0F1BC3-8193-4857-AF1A-8AA1050C379AQ40078937-550CB749-A4A4-4E14-BFF0-A78DF9106BFDQ40146897-57A087B4-9D24-4A71-A4F8-80465E85A14AQ40177234-447AEEFB-0C20-499E-9C85-4025F296C32AQ40289935-29825191-700A-48ED-B64C-0347387A2C0DQ40506121-3AC31840-12D7-442A-A5DC-9A939AEDF051Q40528859-B72A4009-06F0-4861-9793-2BBA421BF871Q41428704-98399F28-547A-4844-A820-890602F95FE0Q42662300-697A8596-5612-4F8D-87AA-5E6106403548Q42788661-71B8F6FD-A84E-4150-8C84-3FA568B4DBC9Q42836670-98CD750B-C2B2-4F98-8AC1-457B27305749Q43057309-EDEC80A4-6D60-48B7-BF35-4105DE2875AFQ43059812-2F0D6F49-CC25-4255-BEA0-19E09188400AQ43230650-4F53ED72-F77C-4262-BE56-AE1D6806C84EQ43772049-F5CD0D72-C812-4E0D-A13D-B375DA69764EQ44295532-02120C72-40BC-4729-A675-C458C4B82FD7Q44332424-F5A59F39-93C4-45FD-AD99-C3C4E2B7BD57Q44628467-C8702510-12F0-4EDE-8C20-D91083AF8D3CQ44939952-2B93A64B-666D-4F45-A928-4E4BE09A7D71Q45063507-A3FB3FFD-D24A-4FBB-AA9F-4A75C39E74D0Q46191601-69513038-B583-49C0-915B-74C079ED2E3C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Jens F. Dahlerup
@ast
Jens F. Dahlerup
@en
Jens F. Dahlerup
@es
Jens F. Dahlerup
@nl
Jens F. Dahlerup
@sl
type
label
Jens F. Dahlerup
@ast
Jens F. Dahlerup
@en
Jens F. Dahlerup
@es
Jens F. Dahlerup
@nl
Jens F. Dahlerup
@sl
altLabel
Change of surname in 1997 from Møller-Petersen to Dahlerup
@en
prefLabel
Jens F. Dahlerup
@ast
Jens F. Dahlerup
@en
Jens F. Dahlerup
@es
Jens F. Dahlerup
@nl
Jens F. Dahlerup
@sl
P1153
P106
P1153
6508257629
7003461497
7005236673
P21
P214
1151246596644132707
P31
P496
0000-0002-1587-7636
P734
P735
P7859
viaf-1151246596644132707